| Summary: | Management of Crohn’s disease (CD) is moving towards the therapeutic goal of mucosal healing and using biomarkers of inflammation, faecal calprotectin (FC) and C-reactive protein (CRP), to monitor patient progress. CALM demonstrated superior mucosal healing in patients whose treatment was escalated based on both symptoms and biomarkers than in patients managed by symptoms alone,1 but the optimal biomarker cut-offs to predict mucosal healing have not been established yet. In this analysis, association of endoscopic outcomes with FC and CRP at cut-offs from CALM was investigated.
|
|---|